**Name:** PABRINEX® Intravenous High Potency (IVHP), Concentrate for Solution for Infusion  
**Prescribing Information.** Please refer to the full Summary of Product Characteristics before prescribing.

**Active Ingredients:** Pabrinex IVHP is presented as a pair of (two) 5ml ampoules labelled No. 1 and No. 2. Each No. 1 ampoule contains thiamine hydrochloride 250mg, riboflavin 4mg and pyridoxine hydrochloride 50mg. Each No. 2 ampoule contains ascorbic acid 500mg, nicotinamide 160mg and glucose (as monohydrate) 1000mg.  
**Indications:** Rapid therapy of severe depletion or malabsorption of the water-soluble vitamins B and C, particularly in alcoholism.  
**Dosage and Administration:** Before administration ensure both the Summary of Product Characteristics and ampoule labels refer to INTRAVENOUS infusion.  
**Adverse Effects:** Hypersensitivity (including anaphylaxis, rash and urticaria), paraesthesia, hypotension, and injection site reactions. Prescribers should consult the summary of product characteristics for further details of side-effects.  
**Contraindications:** Known hypersensitivity to any of the active substances or excipients. **Precautions:** Potentially serious allergic reactions such as anaphylactic shock may occur rarely, during or shortly after administration of Pabrinex IVHP. Symptoms such as sneezing or mild asthma are warning signs that further injections may give rise to anaphylactic shock. Facilities for treating anaphylactic reactions should be available whenever Pabrinex IVHP is administered. To minimise risk, infuse over 30 minutes. **Interactions:** The content of pyridoxine may interfere with the effects of concurrent levodopa therapy. **Pregnancy and Lactation:** No adverse effects have been noted during pregnancy or lactation at recommended doses when used as clinically indicated. The potential risk for humans is unknown. Caution should be exercised when prescribing to pregnant women. **Legal category:** POM. **Marketing Authorisation Holder:** Kyowa Kirin Limited, Galabank Business Park, Galashiels, TD1 1QH, UK. **Marketing Authorisation Number:** Pabrinex IVHP: PL 16508/0049. **NHS price:** Pabrinex IVHP as 6 pairs of 5ml ampoules: £16.23; Pabrinex IVHP as 10 pairs of 5ml ampoules: £22.53. **Date of prescribing information:** June 2018.  
*Pabrinex is a registered trade mark. UK/PAB/0276

---

**Adverse Events should be reported.** Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.  
**Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com

---

**For the Republic of Ireland:**  
**PABRINEX® Intravenous High Potency (IVHP), Concentrate for Solution for Infusion  
Prescribing Information.** Please refer to the full Summary of Product Characteristics before prescribing.

**Name:** PABRINEX® Intravenous High Potency (IVHP), Concentrate for Solution for Infusion.  
**Active Ingredients:** Pabrinex IVHP is presented as a pair of (two) 5ml ampoules labelled No. 1 and No. 2. Each No. 1 ampoule contains thiamine hydrochloride 250mg, riboflavin 4mg and pyridoxine hydrochloride 50mg. Each No. 2 ampoule contains ascorbic acid 500mg, nicotinamide 160mg and glucose (as monohydrate) 1000mg.  
**Indications:** Rapid therapy of severe depletion or malabsorption of the water-soluble vitamins B and C, particularly in alcoholism.  
**Dosage and Administration:** Before administration ensure both the Summary of Product Characteristics and ampoule labels refer to INTRAVENOUS infusion.  
**Adverse Effects:** Hypersensitivity (including anaphylaxis, rash and urticaria), paraesthesia, hypotension, and injection site reactions. Prescribers should consult the summary of product characteristics for further details of side-effects.  
**Contraindications:** Known hypersensitivity to any of the active substances or excipients. **Precautions:** Potentially serious allergic reactions such as anaphylactic shock may occur rarely, during or shortly after administration of Pabrinex IVHP. Symptoms such as sneezing or mild asthma are warning signs that further injections may give rise to anaphylactic shock. Facilities for treating anaphylactic reactions should be available whenever Pabrinex IVHP is administered. To minimise risk, infuse over 30 minutes. **Interactions:** The content of pyridoxine may interfere with the effects of concurrent levodopa therapy. **Pregnancy and Lactation:** No adverse effects have been noted during pregnancy or lactation at recommended doses when used as clinically indicated. The potential risk for humans is unknown. Caution should be exercised when prescribing to pregnant women. **Legal category:** POM. **Marketing Authorisation Holder:** Kyowa Kirin Holdings B.V., Bloemlaan 2, 2132NP, Hoofddorp, Netherlands. **Marketing Authorisation Number:** Pabrinex IVHP: PA 2288/001/001. **Date of prescribing information:** November 2018.  
*Pabrinex is a registered trade mark. IRE/PAB/0033

---

**Adverse Events should be reported.** Information about adverse event reporting can be found at www.hpra.ie.  
**Adverse Events should also be reported to Kyowa Kirin Ltd. on +44 (0)1896 664000, email medinfo@kyowakirin.com